medigraphic.com
ISSN 2448-5640 (Print)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2020, Number 4

<< Back Next >>

Cir Card Mex 2020; 5 (4)

Intraoperative blood red cell saving effect on the homologous blood transfusion in adult patients undergoing heart surgery with cardiopulmonary bypass

Rivera-San Martin Y, Solís-Carmona R, Parra-Argudo MA, Arrieta-Arellano G, Cadena-Estrada JC

Language: Spanish
References: 22
Page: 116-121
PDF size: 203.10 Kb.


ABSTRACT

Introduction. Erythrocyte cell saving is the best choice for the autologous preservation of red blood cells minimizing the damaging effects caused by cardiac surgery. Objective. To analyze the effect of intraoperative erythrocyte cell saving on the homologous transfusion of erythrocyte concentrate in adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). Methods. A quantitative study with a descriptive and cross-sectional design was performed from January 2015 to December 2017 in patients undergoing cardiac surgery with CPB and cell savers. Analysis of the data was done with the SPSS program, version 19. Results. 75% of the total population were men, average age of the studied patients was 59.89 ± 9.39 years (40-81), prior to surgery 62% of patients were treated with anticoagulants. According to the Izaguirre scale 85.2% had a risk of habitual bleeding and the remaining 14.8% had a high risk of bleeding. Conclusions. Patients undergoing a cell saving procedure had a lower risk of exposure to homologous transfusion, mainly to erythrocyte concentrate. This does not completely exclude the risk associated with the use of homologous blood, but decreases it.


REFERENCES

  1. Anestesia Cardiovascular (Spanish Edition) de Ortiz Luna, P. 4a edition. Publishedby Alfil, México (2013).

  2. Organización Mundial de la Salud, Nota Descriptiva. Disponibilidad y seguridadde la sangre a nivel mundial. Ginebra. OMS, 2017. http://bit.ly/1kIvbe5.

  3. Salazar-Ramírez C, Daga-Ruiz D, Cota-Delgado F, Fernández-Aguirre C, Fernández-Añon JM, García-Fernández JM. (2010). Utilidad de la plasmaféresis encuidados intensivos. Med Intensiva 2010;34:74-8.

  4. Induni-López E, Alvarado M, Méndez E, Pucci J. (2003). Autotransfusión y terapiade componentes sanguíneos autológos en cirugía cardíaca: consideracionesgenerales y experiencia en el Hospital México. Rev Costarric Cardiol 2003;5:9-18.

  5. Careaga-Reyna G, Ramírez-Castañeda A, Sánchez-Ramírez O, Jiménez-ValdiviaM, Arellano-Villavicencio Á, Argüero-Sánchez R. Sistema recuperador celular encirugía cardiaca con derivación cardiopulmonar para disminuir el uso de sangrehomóloga. Cir Ciruj 2001;69:291-4.

  6. Secretaria de Salud. Reglamento de la ley general de salud en materia de investigacion.México. Diario Oficial de la Federación. 2014. http://bit.ly/1SBpqPT

  7. Tribunal Internacional de Núremberg, 1947. Ética Médica, Código de Nuremberg,Experimentos médicos permitidos. La Plata Argentina. 1989.

  8. La Asciación Médica Mundial (AMM). DECLARACION DE HELSINKI DELA ASOCIACION MEDICA MUNDIAL. In Principios éticos para las investigacionesmédicas en seres humanos; Octubre 2008; Helsinki.

  9. Cordero R, Vives N, Villalobos F, Vieto P, Cartín J. Plasmaféresis en Costa Rica.Revista Médica de Costa Rica1972;39: 65-75.

  10. Rubens FD, Fergusson D, Wells PS, et al. Platelet-rich plasmapheresis in cardiacsurgery: a meta-analysis of the effect on transfusion requirements. J Thorac CardiovascSurg 1998;116:641-7.

  11. Murphy GJ, Rogers CS, Lansdown WB, et al. Safety, efficacy, and cost of intraoperativecell salvage and autotransfusion after off-pump coronary artery bypasssurgery: a randomized trial. J Thorac Cardiovasc Surg 2005;130: 20-8.

  12. Laub GW, Dharan M, Riebman JB, et al. The impact of intraoperative autotransfusionon cardiac surgery. A prospective randomized double-blind study. Chest1993;104:686-9.

  13. Sorin Group. Sorin Xtra. Manual del Usuario. Sorin Group. 2011. https://www.google.com.mx/search?q=sorin+Group.+Sorin+Xtra.+Manual+del+Usuario.+Sorin+Group.+2011&spell=1&sa=X&ved=2ahUKEwj-hpye6N_qAhVLAp-0JHZiEA5MQBSgAegQICxAs&biw=1398&bih=819. Accessed July 21, 2020.

  14. Rosales-Gutiérrez AO, Galván-Talamantes Y, Espinoza de los Monteros-Estrada I.Técnicas farmacológicas de ahorro hemático. Rev Mex Anest 2015;38:56-64.

  15. Arrieta-Arellano G. Intervenciones para conservar la sangre en cirugía cardíacacon circulación extracorpórea. Rev Mex Enferm Cardiol 2012;20:17-20.

  16. Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated withred blood cell and blood-component transfusion in isolated coronary artery bypassgrafting. Crit Care Med 2006;34:1608-16.

  17. Arrieta AG, Ramírez VYE, Martínez JM. Efecto de las estrategias de conservaciónsanguínea sobre la transfusión en pacientes con circulación extracorpórea. RevMex Enf Cardiol 2016;24:5-11.

  18. Serrano-Valdés X. Hemotransfusión como factor de riesgo en cirugía cardiaca.Arch Cardiol Méx 2006;76:86-91.

  19. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, FerrarisVA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and theSociety of Cardiovascular Anesthesiologists blood conservation clinical practiceguidelines. Ann Thorac Surg 2011;91:944-82.

  20. Souza HJ, Moitinho RF. Strategies to reduce the use of blood components in cardiovascularsurgery. Rev Bras Cir Cardiovasc 2008;23:53-9.

  21. Medina JR. Enfermedades infecciosas transmitidas por transfusión. Panorama internacionaly en México. Gac Méd Méx 2014;150:78-83.

  22. Almeida RM, Leitão L. The use of cell saver system in cardiac surgery with cardiopulmonarybyass. Rev Bras Cir Cardiovasc 2013;28:76-82.




2020     |     www.medigraphic.com